- Home
- IMNM
IMNM
Immunome Inc.
as 05-09-2025 3:37pm EST
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.
| Founded: | 2006 | Country: | United States |
| Employees: | N/A | City: | BOTHELL |
| Market Cap: | 687.8M | IPO Year: | 2020 |
| Target Price: | $26.40 | AVG Volume (30 days): | 1.1M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -5.00 | EPS Growth: | N/A |
| 52 Week Low/High: | $5.15 - $19.07 | Next Earning Date: | 05-16-2025 |
| Revenue: | $9,041,000 | Revenue Growth: | -35.50% |
| Revenue Growth (this year): | -85.5% | Revenue Growth (next year): | 1259.12% |
Stock Insider Trading Activity of Immunome Inc. (IMNM)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| SIEGALL CLAY B | IMNM | President and CEO | Mar 26 '25 | Buy | $7.29 | 137,100 | $999,459.00 | 806,736 | |
| BIENAIME JEAN JACQUES | IMNM | Director | Mar 25 '25 | Buy | $7.78 | 7,800 | $60,684.00 | 31,415 | |
| BIENAIME JEAN JACQUES | IMNM | Director | Mar 24 '25 | Buy | $8.21 | 7,000 | $57,470.00 | 31,415 | |
| Tsai Philip | IMNM | Chief Technology Officer | Mar 24 '25 | Buy | $8.42 | 12,300 | $103,566.00 | 33,300 |
Latest Immunome Inc. News
IMNM Breaking Stock News: Dive into IMNM Ticker-Specific Updates for Smart Investing
Zacks
a day ago
Wall Street Analysts Believe Immunome (IMNM) Could Rally 249.93%: Here's is How to Trade
Business Wire
7 days ago
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Zacks
a month ago
Alnylam (ALNY) Moves 8.5% Higher: Will This Strength Last?
Business Wire
a month ago
Immunome to Present at the 24th Annual Needham Virtual Healthcare Conference
Business Wire
a month ago
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Simply Wall St.
a month ago
Clay Siegall Bought 20% More Shares In Immunome
Argus Research
a month ago
Daily – Vickers Top Buyers & Sellers for 03/27/2025
TipRanks
a month ago
Closing Bell Movers: GameStop gains 7% on earnings, bitcoin announcement
Compare IMNM vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IMNM Immunome Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.